The borrowing extends Dyne's cash runway ahead of clinical catalysts, but the IP collateral and covenant structure warrant monitoring. With $200M drawn and $200M additional capacity tied to milestones/lender approval, the trajectory of the pipeline (muscle disease programs) determines future drawdowns. Watch for next clinical data readouts and any exercise of the $75M discretionary tranche, discretionary lender approval could signal credit concern if DYN delays.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 17 $19.20entry
- T+1 · 5mo ago +3.13%α +2.34% · $19.80
- T+5 · 5mo ago +5.89%α +6.93% · $20.33
- T+20 · 4mo ago +18.33%α +17.02% · $22.72
- T+60 · 2mo ago −5.16%α −8.30% · $18.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics expanded its Hercules Capital debt facility to $400M via a Second Amendment, borrowing an additional $50M on closing. The amendment adds two new $50M tranches and increases the final tranche by $25M, while reducing the minimum cash covenant from 60% to 40% of outstanding obligations and pushing the testing date from January 2027 to July 2027 (extendable to 2028). Outstanding debt post-borrowing is $200M, with up to $200M in additional undrawn tranches available upon milestones or lender approval. The move extends cash runway for a pre-revenue biotech with a $3.0B market cap and 85% analyst buy rating, but adds leverage and secured IP collateral, net neutral for the credit story.
Key Financial Metrics
Key Facts
- Debt facility expanded to an aggregate of up to $400.0 million (from $325M prior structure)
- Second Amendment added two $50M tranches and increased the final tranche by $25M
- Borrowed $50.0 million on the Amendment Closing Date (June 16, 2026)
- Outstanding principal after borrowing: $200.0 million
- Undrawn capacity: $125M (milestone-based) + $75M (lender discretion) = up to $200M
- Minimum cash covenant reduced from 60% to 40% of outstanding obligations, tested only if market cap < $1.65B
- Initial cash covenant testing date moved from Jan 1, 2027 to Jul 1, 2027 (extendable to Jul 1, 2028)
- Interest rate: WSJ Prime + 2.45% with 7.50% floor; interest-only until Jul 1, 2029 (extendable to maturity)
- Maturity date: July 1, 2030
- First-priority security interest on substantially all assets, including IP
Financial Impact
Added $50M cash to balance sheet with $200M drawn total and $200M additional accordion; interest cost ~10.0% (Prime ~7.5% + 2.45%). No revenue or earnings impact reported.
Risk Factors
- Interest rate exposure: floating rate with 7.50% floor could increase costs if Prime rises
- IP collateral: first-priority security interest on all IP means lenders have edge in distress
- Milestone dependence: $125M of undrawn tranches requires clinical/regulatory/commercial milestones, delays could limit access to capital
- Pandemic/clinical risk: pre-revenue biotech with no approved products; stock price volatility could trigger minimum cash covenant (tested only if mkt cap < $1.65B)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001818794-26-000003 |
| Document: 0001818794-26-000003-index-headers.html | 0001818794-26-000003 |
| Document: 0001818794-26-000003-index.html | 0001818794-26-000003 |
| Document: 0001818794-26-000003.txt | 0001818794-26-000003 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers